Candidate: Tocilizumab (Actemra® in the U.S.), alone and in combination with favipiravir (Avigan® in the U.S.)

Category: ANTIBODY

Type: Humanized monoclonal antibody targeting interleukin-6

Status: Peking University First Hospital on March 16 registered an up-to-150 patient study assessing tocilizumab, marketed in China by Roche subsidiary Chugai Pharmaceutical, in combination with the Zhejiang Hisun Pharmaceutical-marketed drug favipiravir in adults with COVID-19 (ChiCTR2000030894). A 94-patient trial assessing Tocilizumab alone has been registered by The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) (ChiCTR2000029765).


COVID-19: 200 Candidates and Counting

To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:

FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.

DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data

KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.

TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.

GEN has also tagged the most common treatment types:

● ANTIVIRAL
● VAX
● ANTIBODY
● RNA

This site uses Akismet to reduce spam. Learn how your comment data is processed.